(NASDAQ: SLN) Silence Therapeutics's forecast annual revenue growth rate of 8.38% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 82.98%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.98%.
Silence Therapeutics's revenue in 2025 is $27,369,000.On average, 4 Wall Street analysts forecast SLN's revenue for 2025 to be $2,990,900,906, with the lowest SLN revenue forecast at $99,191,294, and the highest SLN revenue forecast at $9,277,219,989. On average, 4 Wall Street analysts forecast SLN's revenue for 2026 to be $3,138,695,933, with the lowest SLN revenue forecast at $85,021,109, and the highest SLN revenue forecast at $6,764,846,224.
In 2027, SLN is forecast to generate $5,377,018,324 in revenue, with the lowest revenue forecast at $72,267,942 and the highest revenue forecast at $8,955,556,794.